Want to see BVS full AI Analyst Report?
BVS Stock Chart & Stats
$11.80
$0.32(2.79%)
At close: 4:00 PM EDT
$11.80
$0.32(2.79%)
Day’s Range― - ―
52-Week Range$5.81 - $13.55
Previous CloseN/A
Volume472.86K
Average Volume (3M)654.88K
Market Cap
$1.10B
Enterprise Value$923.81
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$272.08M
Price to Earnings (P/E)31.2
Beta0.81
Next Earnings
Aug 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding67,748,050
10 Day Avg. Volume553,877
30 Day Avg. Volume654,875
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.00Price Target Upside27.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)$605.75M
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong trailing‑12‑month operating and free cash flow provides durable internal funding for debt paydown, R&D and commercial investments. Raised full‑year cash from operations guidance ($84–$89M) and a large YoY CFO uplift support reinvestment without heavy external financing, improving financial resilience over multiple quarters.
De‑leveraging / Balance SheetMaterial improvement in leverage and a clearer path to sub‑2.0x net leverage reduces execution risk and interest burden. The shift from high leverage in 2023–2025 to a healthier equity/debt mix increases strategic optionality for targeted investment and decreases refinancing sensitivity over the medium term.
Margin Recovery And ProfitabilitySustained high gross margins and a return to positive net margin create durable operating leverage for the business. This margin strength underpins management's ability to target ~20% adjusted EBITDA, fund selective growth initiatives, and withstand pricing or reimbursement variability across orthopedic product lines.
Bears Say
Remaining Debt LevelAlthough leverage has declined, the $272M debt balance is still sizable and could constrain strategic flexibility if cash generation weakens. Remaining leverage increases sensitivity to slower revenue or margin setbacks and could limit pace of discretionary investment or M&A until net leverage targets are firmly achieved.
One‑time Items Affecting MarginsPart of the recent margin and gross‑profit improvement was driven by a one‑time rebate and tariff refund. That reduces the persistence of the quarter's outperformance and creates uncertainty around forward margin sustainability, requiring underlying operational gains to validate higher profitability levels.
Early‑stage Growth Drivers / Execution RiskKey new growth initiatives (PNS, PRP, Ultrasonics) are nascent and require multi‑quarter commercialization, clinical support and surgeon training. Their long lead times and upfront investment raise execution risk and make near‑term revenue consistency dependent on successful scaling of sales and clinical adoption.
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $5.81 and its highest was $13.55 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $1.10B.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on May 06, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.069 by $0.081.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Undervalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.22.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 67,748,050 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.15 in its last earnings report, beating expectations of $0.069. Following the earnings report the stock price went up 2.247%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (27.12% Upside)
$15.00 (27.12% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 359.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.5%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.91%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus Inc. (BVS) is a medical technology company focused on orthobiologic and orthopedic solutions. The company develops, manufactures, and commercializes products used primarily by orthopedic and sports medicine clinicians to support bone healing, joint preservation, and pain relief, including bone growth stimulation devices and therapies used in musculoskeletal care.
BVS Company Deck
BVS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong financial momentum: solid revenue growth (+7%), robust adjusted EBITDA expansion (+24%), improved margins and materially stronger cash flow (+$28M YoY), along with raised EPS and cash guidance. Management is accelerating targeted investments (primarily into PNS, PRP, Ultrasonics and International) and added senior leadership to scale new businesses. Offsetting items include a one-time favorable rebate that boosted Q1 results, near-term margin volatility as investments ramp, early-stage nature of new growth drivers, distributor inventory/timing headwinds in Pain, and a still-material debt balance ($272M) that remains a focus. Overall, the positives (growth, profitability, cash generation and proactive reinvestment) outweigh the manageable near-term challenges.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$15.00
▲(27.12% Upside)
Technical Analysis
Ownership Overview
32.13% Insiders
8.71% Mutual Funds
0.90% Other Institutional Investors
46.92% Public Companies and
Individual Investors